Papillary thyroid carcinoma: New research
In the presentation “Impact of Radioactive Iodine on Survival in Papillary Thyroid Carcinoma,” Paritosh Suman, M.D. and colleagues from North Shore University Health System (Evanston, IL), explore the benefit of (RAI) treatment following surgery to remove the thyroid in patients with PTC, and whether survival benefit relates to tumor size. In a retrospective study of nearly 285,000 patients treated over 13 years, with a mean follow-up of 7 years, the authors found that 47% of patients had RAI therapy and it showed a small but statistically significant survival benefit regardless of the tumor size. Carrie Lubitz, M.D., M.P.H., Massachusetts General Hospital (Boston), and coauthors previously described a novel blood-based assay for detecting the V600E mutation in the BRAF gene in patients with melanoma…